Novo Nordisk's (DK:NOVO.B) next-gen medication is called CagriSema. It's a once-weekly shot that combines a long-acting amylin analogue and Wegovy. Clinical trials found that patients taking CagriSema ...
Wegovy maker Novo Nordisk filed for U.S. FDA approval of CagriSema, a once-weekly shot that combines two compounds to treat obesity.
A selective androgen receptor modulator combined with a GLP-1 may induce weight loss for older adults with obesity while ...
Doctors and groups representing employers said they’re increasingly hearing about companies cutting weight loss drugs out of ...
President Trump launched TrumpRx, a new initiative aiming to slash prescription drug costs by forging direct deals with ...
Novo Nordisk stock plunges 42% so far in 2025 as GLP-1 competition, price cuts, guidance trims and restructuring plans cloud ...
People paying out of pocket for Ozempic or Wegovy may soon see lower costs, as Novo Nordisk rolls out new price discounts for its popular GLP-1 medications.
The federal government has announced the results of the latest round of Medicare drug price negotiations: 15 lower drug prices for Medicare to go into effect in 2027. Medicare will get a 71% discount ...
It’s evident that there is still a challenge with access to mental health support. There’s a provider shortage, and the available providers’ time slots fill up quickly. But more than that, receiving ...
Experts say lower prices may help access but could also cause employers to drop insurance coverage WEDNESDAY, Nov. 19, 2025 (HealthDay News) — People paying out of pocket for Ozempic or Wegovy may ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback